The BXPC-3 cell line is a human pancreatic adenocarcinoma cell line that was originally derived from a pancreatic tumor from a 61-year-old female patient. The BXPC-3 cell line is commonly used in cancer research to study pancreatic cancer biology and to evaluate potential therapies for this disease.

The BXPC-3 cell line is characterized by its high tumorigenicity, rapid growth rate, and invasive behavior, which closely resemble the features of human pancreatic adenocarcinoma. The BXPC-3 cell line is commonly used in preclinical studies to investigate the mechanisms of pancreatic cancer development and progression, identify potential therapeutic targets, and evaluate the efficacy and toxicity of various treatment modalities, such as chemotherapy, immunotherapy, and gene therapy.

The BXPC-3 cell line has been extensively characterized, and its genome has been sequenced, making it a valuable tool for molecular and genetic studies of pancreatic cancer. Additionally, the BXPC-3 cell line has been used in studies exploring the role of the tumor microenvironment in cancer progression and the response to therapy.

To maintain the BXPC-3 cell line in culture, suitable culture medium is required, and the cells need to be maintained at appropriate temperature and humidity conditions. Regular monitoring of cell confluence and viability is also essential.

Overall, the BXPC-3 cell line is a valuable resource for cancer research, offering a powerful model system for investigating the biology of pancreatic adenocarcinoma and developing new therapies for this disease.